School of Medicine


Showing 61-70 of 73 Results

  • David A. Relman

    David A. Relman

    Thomas C. and Joan M. Merigan Professor and Professor of Microbiology and Immunology

    Current Research and Scholarly InterestsMy investigative program focuses on human-microbe interactions and human microbial ecology, and primarily concerns the ecology of human indigenous microbial communities; a secondary interest concerns the classification of humans with systemic infectious diseases, based on features of genome-wide gene transcript abundance patterns and pther aspects of the host response.

  • Michael J Rosen, MD, MSCI

    Michael J Rosen, MD, MSCI

    Stanford University Endowed Professor for Pediatric IBD and Celiac Disease

    BioI am a pediatric gastroenterologist and physician scientist, who has been devoted to inflammatory bowel disease (IBD) research since beginning medical training over 20 years ago. I am also Director of the Stanford Center for Pediatric IBD and Celiac Disease. I have expertise crossing mucosal immunology and epithelial biology, formal training and experience in clinical and translational investigation with human biospecimens, and direct insight regarding the important clinical challenges caring for children with complicated IBD. My translational research program focuses on how the immune system regulates epithelial function in chronic intestinal inflammation as it relates to IBD. My clinical research program has focused on optimization of anti-TNF therapy in pediatric IBD, and in particular acute severe ulcerative colitis (ASUC). My laboratory has demonstrated a protective role for IL33, a cytokine that induces type 2 cytokines from T cells an innate lymphoid cells (ILCs), in acute oxazolone colitis through preservation of epithelial goblet cells and barrier function. In line with this finding, we have also shown in a large prospective patient cohort that mucosal expression of type 2 and type 17 immune response genes distinguishes ulcerative colitis (UC) from colon-only Crohn’s disease, and that type 2 gene expression is associated with superior clinical outcome in pediatric UC. We have now developed an organoid-immune cell in vitro culture system to demonstrate the ILC2-dependent mechanism through which IL33 induces goblet cell differentiation in the intestinal epithelium. I led the multicenter study Anti-TNF for Refractory Colitis in Hospitalized Children (ARCH) Study, which aims to establish determinants of anti-TNF response in pediatric ASUC and currently Co-Chair the Crohn's & Colitis Foundations Cohort for Pediatric Translational and Clinical Research in IBD (CAPTURE IBD) and PRO-KIIDS Pediatric IBD clinical research network.

  • Eric Sibley, M.D., Ph.D.

    Eric Sibley, M.D., Ph.D.

    Professor of Pediatrics (Gastroenterology)

    Current Research and Scholarly InterestsMolecular Regulation of Intestinal Development and Maturation. We study transcriptional mechanisms regulating the spatial and temporal restriction of intestine-specific gene expression during gut development. Our approach is to characterize the function of gene-specific DNA cis elements and interacting nuclear proteins in cell culture and in transgenic animals. The goal is to relate the gene-specific control mechanisms to the broader pathways specifying acquisition of gut phenotypes.

  • Sidhartha Sinha

    Sidhartha Sinha

    Assistant Professor of Medicine (Gastroenterology and Hepatology)

    Current Research and Scholarly InterestsThere are two primary and overlapping emphases of my research, both of which are driven and united by needs-based innovation and translational potential:

    (1) Understanding the microenvironment of the inflamed versus normal gut in order to identify better therapeutic targets for people with immune-¬mediated GI disorders. Here, our investigations include understanding the influence and interactions of pharmacologic and dietary interventions on gut microbiome/metabolomic changes and the host immune response. In the context of providing patients with new understanding and solutions for their disease, I have led and advised on the design of both pilot and large clinical trials (including new FDA approved therapies) for anti-inflammatory therapies;

    (2) Applying novel approaches and technologies (including natural language processing, computer vision, and reinforcement learning) to identify and address unmet clinical needs. In this area we have ongoing and published efforts in my lab to validate and develop solutions to pressing clinical needs. We have developed/led new drug delivery technologies with a multidisciplinary team that have shown strong potential in ongoing human IBD clinical trials. My lab has utilized both supervised and unsupervised approaches to analyze social media discourse and unstructured data sets for identifying patient needs that are rarely addressed in clinical settings. We have gained insights into patient perceptions around preventative health interventions, such as health screening and diet, including the dearth of evidence-based dietary recommendations to treat IBD (despite strong patient desire for solutions in this domain).

  • Michael Snyder, Ph.D.

    Michael Snyder, Ph.D.

    Stanford W. Ascherman Professor of Genetics

    Current Research and Scholarly InterestsOur laboratory use different omics approaches to study a) regulatory networks, b) intra- and inter-species variation which differs primarily at the level of regulatory information c) human health and disease. For the later we have established integrated Personal Omics Profiling (iPOP), an analysis that combines longitudinal analyses of genomic, transcriptomic, proteomic, metabolomic, DNA methylation, microbiome and autoantibody profiles to monitor healthy and disease states

  • Justin L. Sonnenburg

    Justin L. Sonnenburg

    Alex and Susie Algard Endowed Professor

    Current Research and Scholarly InterestsThe goals of the Sonnenburg Lab research program are to (i) elucidate the basic mechanisms that underlie dynamics within the gut microbiota and (ii) devise and implement strategies to prevent and treat disease in humans via the gut microbiota. We investigate the principles that govern gut microbial community function and interaction with the host using a broad range of experimental approaches including studies of microbiomes in diverse human cohorts.

  • Sarah Streett

    Sarah Streett

    Clinical Professor, Medicine - Gastroenterology & Hepatology

    BioDr. Sarah Streett is a Clinical Professor of Medicine, the Director of Inflammatory Bowel Disease Education at Stanford, and she is passionate about taking care of people with IBD. She is a national expert in treating complex IBD and initiated a multi-disciplinary approach to care with colorectal surgery, pediatrics, and nutrition. In 2018 she received the Champion of Hope Award from the Crohn’s and Colitis Foundation and serves on their National Scientific Advisory Committee. Her interests focus on fertility and pregnancy in people with IBD, developing precision approaches to IBD therapy, and the role that the microbiome and diet play in its pathogenesis. She is a primary investigator of the Stanford IBD Registry and has research projects focused on optimizing clinical outcomes in IBD, the role of the microbiota and diet in IBD and pregnancy, and applying new technologies to individualizing therapy for IBD. She is also the primary investigator on multiple industry-sponsored IBD trials.

    Teaching is a top priority for Dr. Streett who feels that mentoring fellows in the development of their careers is a privilege. She has held many national leadership roles in the American Gastroenterological Association, where she has been Chair of the Practice Management and Economics Committee, and currently serves on the Government Affairs Committee. She also an appointed member of the Gastrointestinal Drug Advisory Committee at the FDA. She has represented the interests of gastroenterologists and their patients on Capitol Hill numerous times. Dr. Streett believes strongly in a collaborative approach to give patients personalized care based on the latest therapies for the treatment of IBD and is committed to mentoring the next generation of experts in the field.

  • Ali Bin Syed

    Ali Bin Syed

    Clinical Assistant Professor, Radiology - Pediatric Radiology

    BioDr. Syed is a member of the divisions of Pediatric Radiology and Body MRI and serves as the Medical Director of Pediatric MRI at Stanford. Dr. Syed has received subspecialty training in adult body imaging, pediatric body imaging, congenital cardiac imaging, and musculoskeletal imaging. His clinical interests include MR imaging of pediatric and adult hepatobiliary disorders, inflammatory bowel disease, gynecologic pathology, and congenital heart disease. He is also an active researcher and works with engineers and scientists to translate technical innovations in MRI into improved patient care. His recent work focuses on translation of machine learning techniques for rapid, robust MRI in children and adults.